Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation

British Journal of Haematology

Volumn 169, Issue 6, 2015, Pages 851-858

  Weinstock, Mathew ^a   Aljawai, Yosra ^a   Morgan, Elizabeth A ^a   Laubach, Jacob ^a   Gannon, Muriel ^a   Roccaro, Aldo M ^a   Varga, Cindy ^a   Mitsiades, Constantine S ^a   Paba Prada, Claudia ^a   Schlossman, Robert ^a   Munshi, Nikhil ^a   Anderson, Kenneth C ^a   Richardson, Paul P ^a   Weller, Edie ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD44; Extramedullary; Multiple myeloma; Novel agents; Stem cell transplantation

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HERMES ANTIGEN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTRAMEDULLARY DISEASE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR BIOPSY; BIOPSY; CENTRAL NERVOUS SYSTEM; HEAD AND NECK NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; INCIDENCE; LYMPH NODE; MORTALITY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

BIOPSY; CENTRAL NERVOUS SYSTEM; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LYMPH NODES; MALE; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84930275502     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13383     Document Type: Article

References (20)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneauve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
2. Barlogie, B., Smallwood, L., Smith, T. & Alexanian, R. (1989) High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Annals of Internal Medicine, 110, 521-525.
3. Bartel, T.B., Haessler, J., Brown, T.L., Shaughnessy, Jr, J.D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J. & Barlogie, B. (2009) F-18 fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114, 2068-2076.
4. Blade, J., Lust, J.A. & Kyle, R.A. (1994) Immuglobulin D multiple myeloma: presenting features, reponse to therapy, and survival in a series of 53 cases. Journal of Clinical Oncology, 12, 2398-2404.
5. Blade, J., Kyle, R.A. & Greipp, P.R. (1996) Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. British Journal of Haematology, 93, 345-351.
6. Blade, J., Fernandez de Larrea, C., Rosinol, L., Cibeira, M.T., Jimenez, R. & Powles, R. (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology, 29, 3805-3812.
7. Dahl, I.M., Rasmussen, T., Kauric, G. & Husebekk, A. (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. British Journal of Haematology, 116, 273-277.
8. Dimopoulous, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
9. Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J. & Cronin, K.A. (eds) (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on Novemner 2011 SEER data submission, posted to the SEER website, 2012. Accessed 1 November 2014.
10. Raanani, P., Shpilberg, O. & Ben-Bassat, I. (2007) Extramedullary disease and targeted therapies for hematologic malignancies-is the association real? Annals of Oncology, 18, 7-12.
11. Rajkumar, S.V., Blood, E., Vessole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
12. Rasche, L., Bernard, C., Topp, M., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H. & Knop, S. (2012) Features of extramedulllary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Annals of Hematology, 91, 1031-1037.
13. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
14. Short, K.D., Rajkumar, S.V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V., Kyle, R.A. & Lacy, M.Q. (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of Pomalidomide on extramedullary myeloma. Leukemia, 25, 906-908.
15. Stauder, R., Van Driel, M., Schwärzler, C., Thaler, J., Lokhorst, H.M., Kreuser, E.D., Bloem, A.C., Günthert, U. & Eisterer, W. (1996) Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood, 88, 3101-3108.
16. Stessman, H.A., Mansoor, A., Zhan, F., Janz, S., Linden, M.A., Baughn, L.B. & Van Ness, B. (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia, 27, 2075-2077.
17. Usmani, S.Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., Van Rhee, F., Crowley, J. & Barlogie, B. (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is overrepresented in high risk disease even in the era of novel agents. Haematologica, 97, 1761-1767.
18. Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. & Lazzarino, M. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 21, 325-330.
19. Weinstock, M. & Ghobrial, I.M. (2012) Extramedullary multiple myeloma. Leukemia and Lymphoma, 54, 1135-1141.
20. Zheng, W., Liu, D., Fan, X., Powers, L., Goswami, M., Hu, Y., Lin, P., Medeiros, L.J. & Wang, S.A. (2013) Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom. 4:222-228.